Workflow
华北制药(600812) - 2022 Q3 - 季度财报
NCPCNCPC(SH:600812)2022-10-26 16:00

Financial Performance - The company's operating revenue for Q3 2022 was approximately ¥2.59 billion, a decrease of 0.35% compared to the same period last year[7]. - Net profit attributable to shareholders was approximately ¥5.56 million, down 66.85% year-on-year, while year-to-date net profit increased by 113.39% to approximately ¥37.94 million[7][13]. - Basic and diluted earnings per share were both ¥0.003, reflecting a 70% decrease compared to the previous year[9]. - Total operating revenue for the first three quarters of 2022 was CNY 7,873,258,693.27, a decrease of 3.82% compared to CNY 8,186,782,145.76 in the same period of 2021[32]. - Net profit attributable to shareholders of the parent company for Q3 2022 was CNY 37,935,682.09, an increase of 113.57% from CNY 17,777,880.20 in Q3 2021[36]. - The company reported a total comprehensive income of CNY 62,428,111.51 for Q3 2022, compared to CNY 23,390,347.48 in Q3 2021, indicating a significant increase[38]. - The company’s basic and diluted earnings per share for Q3 2022 were both CNY 0.022, doubling from CNY 0.011 in Q3 2021[38]. - The net profit for the third quarter of 2022 was approximately ¥331.97 million, compared to ¥140.17 million in the same quarter of 2021, indicating a significant increase of 136.5%[54]. Cash Flow - The net cash flow from operating activities for the year-to-date period was approximately ¥533 million, a decrease of 17.04% compared to the same period last year[9]. - The company reported a decrease in cash flow from operating activities, impacting liquidity and operational flexibility[23]. - Cash inflow from operating activities totaled CNY 7,580,741,283.11, an increase from CNY 6,942,108,928.76 in the previous period, representing a growth of approximately 9.2%[42]. - Cash outflow from operating activities was CNY 7,047,722,200.67, compared to CNY 6,299,646,223.30 in the prior period, indicating an increase of about 11.9%[42]. - Net cash flow from operating activities decreased to CNY 533,019,082.44 from CNY 642,462,705.46, reflecting a decline of approximately 17%[42]. - Cash inflow from financing activities amounted to CNY 8,684,036,714.11, up from CNY 8,521,717,205.00, marking an increase of about 1.9%[44]. - Cash outflow from financing activities rose significantly to CNY 11,996,243,011.53 from CNY 7,462,991,263.62, representing an increase of approximately 60.5%[44]. - The net cash flow from financing activities showed a negative balance of CNY -3,312,206,297.42, compared to a positive CNY 1,058,725,941.38 in the previous period[44]. - Cash flow from operating activities generated a net amount of approximately ¥399.07 million in 2022, down from ¥489.90 million in 2021, a decrease of 18.5%[56]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥23.16 billion, a decrease of 7.11% year-on-year[9]. - The company's equity attributable to shareholders was approximately ¥6.03 billion, down 0.88% from the previous year[9]. - The company's total assets amounted to CNY 23,156,852,612.93, a decrease from CNY 24,929,934,674.93 at the end of 2021[23]. - The company's current assets decreased to CNY 10,948,563,970.74 from CNY 12,712,195,682.24 year-over-year[27]. - The company's total liabilities decreased to CNY 16,193,809,118.95 from CNY 17,912,703,964.04[30]. - The total liabilities and shareholders' equity as of the end of the reporting period was CNY 23,156,852,612.93, down from CNY 24,929,934,674.93[32]. - The total liabilities decreased to approximately ¥11.63 billion in 2022 from ¥13.44 billion in 2021, a reduction of 13.5%[50]. - The total equity increased to approximately ¥7.07 billion in 2022 from ¥6.84 billion in 2021, showing a growth of 3.4%[50]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 92,202[14]. - The largest shareholder, Jizhong Energy Co., Ltd., held 24.08% of the shares, while Huabei Pharmaceutical Group held 19.90%[14]. Accounting Changes - The company has implemented changes in accounting practices affecting the presentation of transportation costs in the income statement, which do not impact net profit or net assets[9]. - The company has adopted new accounting standards starting from 2022, which may affect the financial statements[58].